The key catalyst to watch is the launch of human investigational studies later this quarter and the magnitude of first StereoCED revenue.
Price Chart
Executive Summary
NeuroOne Medical Technologies (NMTC) announced successful completion of three large-animal procedures using its next-generation StereoCED platform for robotic-assisted drug delivery. The company expects to recognize first StereoCED revenue in fiscal Q4 2026 and plans to launch human investigational clinical studies later this quarter. This is a positive preclinical milestone for a novel drug delivery platform, but no financial figures or revenue amounts were disclosed, and the product is not yet approved for commercial use.
Key Facts
- Three large-animal procedures successfully completed using the StereoCED platform at the University of Minnesota.
- In two of three procedures, the drug delivery electrodes both delivered a study agent and recorded intracranial electrophysiological activity from the same targeted regions — a first in convection-enhanced delivery.
- Development of StereoCED devices for animal use finished ahead of schedule, enabling earlier-than-anticipated sales.
- NeuroOne expects to recognize first StereoCED revenue from this research program in fiscal Q4 2026.
- Human investigational clinical studies planned for launch by end of fiscal Q4 2026.
- StereoCED Drug Delivery System is not approved/cleared for commercial use by any regulatory agency.
Financial Impact
First StereoCED revenue expected in fiscal Q4 2026; no dollar amounts disclosed.
Risk Factors
- StereoCED is not yet approved for commercial use by any regulatory agency.
- Forward-looking statements about human studies and revenue timing are subject to regulatory and clinical risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (NMTC) — Batch item 1 | 0001213900-26-094174 |
| Document: 0001213900-26-094174-index.html | 0001213900-26-094174 |
| Document: 0001213900-26-094174.txt | 0001213900-26-094174 |
| 8-K Filing (NMTC) — Batch item 4 | 0001213900-26-094174 |
| Document: 0001213900-26-094174-index.html | 0001213900-26-094174 |
| Document: 0001213900-26-094174.txt | 0001213900-26-094174 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8039 (−27.90%) |
Oct 5, 2026 21d ago | Press Release | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8039 (−27.90%) |
Aug 27, 2026 8w ago | 8-K | $1.98 $1.77 | ▼ −10.61% | ▼ −10.38% | $0.8039 (−59.40%) |
Aug 13, 2026 10w ago | 8-K | $1.83 $1.94 | ▲ +6.01% | ▲ +6.21% | $0.8039 (−56.07%) |
Jun 12, 2026 19w ago | 424B5 / 8-K | $3.32 $3.25 | ▲ +2.11% | ▲ +1.51% | $0.8039 (+75.79%) |
May 22, 2026 22w ago | 8-K | $3.87 $3.73 | ▲ +3.62% | ▲ +3.63% | $0.8039 (+79.23%) |
May 12, 2026 23w ago | 8-K | $4.39 $4.51 | ▲ +2.73% | ▲ +2.16% | $0.8039 (−81.69%) |
May 4, 2026 25w ago | 8-K | $4.49 $4.43 | ▼ −1.34% | ▼ −2.13% | $0.8039 (−82.10%) |
Apr 30, 2026 25w ago | 8-K | $4.70 $4.35 | ▼ −7.45% | ▼ −7.67% | $0.8039 (−82.90%) |
Feb 25, 2026 34w ago | 8-K | $4.15 $4.02 | ▼ −3.04% | ▼ −2.59% | $0.8039 (−80.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers